

Very Early PCSK9 Inhibition for Acute Myocardial Infarction

NCT07208006

Status	RECRUITING
Phase	Not Applicable
Sponsor	Shanghai Zhongshan Hospital
Enrollment	1,518 participants

Key Eligibility Criteria

Inclusion (5)

- Age \geq 18 years.
- Acute myocardial infarction (AMI) onset within 30 days (first hospitalization with a confirmed diagnosis of STEMI or NSTEMI).
- Multivessel coronary artery disease; successful percutaneous coronary intervention (PCI) of the culprit lesion in the infarct-related artery (IRA), including stent implantation and/or balloon angioplasty and/or thrombus aspiration.
- At least one angiographically assessed diameter stenosis \geq 50% in a non-infarct-related artery (non-IRA) with a reference vessel diameter \geq 2.5 mm.
- Able to understand and willing to provide written informed consent, comply with prescribed medical therapy, and complete the required follow-up.

Exclusion (10)

- Cardiogenic shock or severe heart failure (Killip class IV).
- Serum creatinine $>$ 150 μ mol/L or glomerular filtration rate (GFR) $<$ 45 mL/min/1.73 m² calculated by the Cockcroft-Gault equation.
- Known or suspected infective endocarditis or active systemic infection.
- Clinically significant coagulation abnormalities, or anticipated inability to tolerate long-term antiplatelet therapy.
- Pregnant or breastfeeding women, women planning pregnancy within 1 year, or those unwilling to use effective contraception.
- ... and 5 more (see full listing online)

Locations (1 total)

Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China